Dr. Ulahannan on the VALENTINO Trial in Advanced CRC

Video

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the VALENTINO trial in advanced colorectal cancer (CRC).

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the VALENTINO trial in advanced colorectal cancer (CRC).

There is a lot of existing data for bevacizumab (Avastin) in combination with 5-fluorouracil (5-FU) in the maintenance setting. This regimen is often used by physicians to help enhance a patient’s quality of life, says Ulahannan. However, there are limited data to support the use of anti-EGFR agents in the maintenance setting.

The phase II VALENTINO study was a noninferior trial looking at panitumumab (Vectibix) as maintenance therapy versus panitumumab and 5-FU. The study met its endpoint. Physicians can now use this regimen as an effective maintenance treatment for patients with RAS wild-type CRC, states Ulahannan.

The study is unlikely to change the standard of care in the maintenance setting as 5-FU is already the basis of maintenance approaches whether combined with a targeted therapy such as VEGFR-targeted agent like bevacizumab (Avastin) or an EGFR-targeting therapy like panitumumab or cetuximab (Erbitux).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD